Myocardial Infarction Clinical Trial
Official title:
Diagnostic and Prognostic Utility of Pentraxin 3 in Patients With Acute ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
A number of inflammatory markers have been recognized, among which the acute phase reactant
C-reactive protein showed a positive correlation with the risk of coronary artery disease in
both healthy individuals and those at high risk .
Pentraxin 3 is expressed in atherosclerotic plaques, mainly in macrophages and neutrophils,
suggesting that pentraxin 3 may be involved in the progression of atherosclerotic plaque.
- A number of studies demonstrated that increased levels of Pentraxin 3 were associated
with the presence and increased severity of coronary artery disease in clinically stable
patients undergoing elective coronary angiography .
- Pentraxin 3 levels peak at about 7 h after acute MI, which is substantially earlier than
CRP, and thus PTX3 could be a better independent predictor of CHD than CRP .
- Recently, it was shown that the number of the involved vessels, MI type, stent length,
culprit lesion, and the need for PCI all had a significant relation with abnormal
Pentraxin 3 levels , however, it was not studied with respect of its relation with
postprocedural angiographic and clinical outcomes.
We thought to evaluate the role of pentraxin-3 on the preprocedural determinants (Grace
score, type of MI, culprit lesion, lesion length, pre-procedural TIMI flow, thrombus burden,
severity and complexity of CAD as determined by Syntax score and procedural outcome
(post-procedural TIMI flow, no reflow and myocardial perfusion assessed by myocardial blush
grade as well as the inhospital clinical outcome of primary Percutaneous coronary
intervention in patients with acute ST elevation myocardial infarction.
A number of inflammatory markers have been recognized, among which the acute phase reactant
C-reactive protein showed a positive correlation with the risk of coronary artery disease in
both healthy individuals and those at high risk .
Pentraxin 3 is expressed in atherosclerotic plaques, mainly in macrophages and neutrophils,
suggesting that pentraxin 3 may be involved in the progression of atherosclerotic plaque.
- A number of studies demonstrated that increased levels of Pentraxin 3 were associated
with the presence and increased severity of coronary artery disease in clinically stable
patients undergoing elective coronary angiography .
- Pentraxin 3 levels peak at about 7 h after acute MI, which is substantially earlier than
CRP, and thus PTX3 could be a better independent predictor of CHD than CRP .
- Recently, it was shown that the number of the involved vessels, MI type, stent length,
culprit lesion, and the need for PCI all had a significant relation with abnormal
Pentraxin 3 levels , however, it was not studied with respect of its relation with
postprocedural angiographic and clinical outcomes.
We thought to evaluate the role of pentraxin-3 on the preprocedural determinants (Grace
score, type of MI, culprit lesion, lesion length, pre-procedural TIMI flow, thrombus burden,
severity and complexity of CAD as determined by Syntax score and procedural outcome
(post-procedural TIMI flow, no reflow and myocardial perfusion assessed by myocardial blush
grade as well as the inhospital clinical outcome of primary Percutaneous coronary
intervention in patients with acute ST elevation myocardial infarction.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
| Completed |
NCT04507529 -
Peer-mentor Support for Older Vulnerable Myocardial Infarction Patients
|
N/A | |
| Recruiting |
NCT06066970 -
Cardiac Biomarkers for the Quantification of Myocardial Damage After Cardiac Surgery
|
||
| Recruiting |
NCT03620266 -
Effects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI
|
N/A | |
| Completed |
NCT04097912 -
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
|
||
| Completed |
NCT04153006 -
Comparison of Fingerstick Versus Venous Sample for Troponin I.
|
||
| Completed |
NCT03668587 -
Feasibility and Security of a Rapid Rule-out and rule-in Troponin Protocol in the Management of NSTEMI in an Emergency Departement
|
||
| Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
| Completed |
NCT03076801 -
Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?
|
N/A | |
| Recruiting |
NCT05371470 -
Voice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation
|
N/A | |
| Recruiting |
NCT04562272 -
Attenuation of Post-infarct LV Remodeling by Mechanical Unloading Using Impella-CP
|
N/A | |
| Completed |
NCT04584645 -
A Digital Flu Intervention for People With Cardiovascular Conditions
|
N/A | |
| Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
| Not yet recruiting |
NCT06007950 -
Time-restricted Eating Study (TRES): Impacts on Anthropometric, Cardiometabolic and Cardiovascular Health
|
N/A | |
| Withdrawn |
NCT05327855 -
Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)
|
Phase 2 | |
| Recruiting |
NCT02876952 -
High Intensity Aerobic Interval Training With Mediterranean Diet Recommendations in Post-Myocardial Infarct Patients
|
N/A | |
| Completed |
NCT02917213 -
Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
|
||
| Completed |
NCT02711631 -
Feasibility and Effectiveness of Remote Virtual Reality-Based Cardiac Rehabilitation
|
N/A | |
| Completed |
NCT02382731 -
Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction
|
N/A | |
| Completed |
NCT02552407 -
Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis
|
N/A |